Latest News

Over the last several decades the diagnosis of prostate cancer has been fraught with uncertainty with traditional systematic biopsies resulting in 30 to 40% rates of upgrading at the time of prostatectomy and failing to diagnose many high-grade cancers. In the modern age, however, we have found that MRI targeted biopsy can lead to substantial […]

A variety of minimally invasive surgical therapies for the treatment of benign prostatic hyperplasia (BPH) have been introduced in recent years with a significant shift towards outpatient procedures. Early studies suggest that these therapies provide adequate symptomatic relief while minimizing some of the disadvantages associated with standard surgical approaches. However, understanding their unique roles in […]

Radiation therapy is commonly used for the definitive and palliative treatment of pelvic malignancies. Secondary pelvic cancers have been reported after radiation therapy, including radiation-associated muscle-invasive bladder cancer (RA-MIBC). The treatment of these cancers poses a challenge due to their inherent resistance and the risk of surgical and re-irradiation options.

The phase III FLAME trial (NCT01168479) showed an increase in five-year biochemical disease-free survival, with no significant increase in toxicity when adding a focal boost to external beam radiotherapy (EBRT) for localized prostate cancer [Kerkmeijer et al.

Is anogenital distance (AGD) shorter in testicular cancer (TC) survivors than in men from the general population, and is AGD affected by testosterone replacement therapy in adulthood? AGD, measured as distance from anus to scrotum (AGDas), is shorter in TC survivors and does not change as a result of testosterone replacement therapy.

Immune-checkpoint-inhibitors (ICIs) have become the cornerstone of metastatic renal-cell-carcinoma (mRCC) therapy. However, data are limited regarding clinical outcomes by race. In this study, we compared the real-world outcomes between African American (AA) and Caucasian mRCC patients treated with ICIs.

To evaluate the learning curve (LC) of two urology residents in the execution of fusion biopsy (FB) in terms of overall prostate cancer (PCa) and clinically significant (cs) PCa detection rate (DR) and according to different characteristics of the lesions on MRI MATERIAL AND METHODS: We analyzed data from our prospective maintained FB database between […]

Safety profiles of abiraterone and enzalutamide mainly rely on phase III clinical trials. Our objective was to estimate the incidence rate ratio (IRR) for certain adverse events leading in real life to hospitalization (atrial fibrillation, acute heart failure, ischemic heart disease, acute kidney injury (AKI), ischemic stroke, torsade de pointe/QT interval prolongation, hepatitis, and seizure), […]

Immune checkpoint inhibitors (ICIs) have led to a paradigm change in the management of metastatic renal cell carcinoma (mRCC). Prospective trials have focused on ICI treatment in the first or second line.

While [177Lu]Lu-PSMA radioligand therapy is currently only applied in end-stage metastatic castrate-resistant prostate cancer (mCRPC) patients, also low-volume hormone-sensitive metastatic prostate cancer (mHSPC) patients can benefit from it.